Kayden Tanner

Dr. Kayden Tanner

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2026 in Equine Veterinary Education
Verified
Journal Article
Open access
KTKayden Tanner
Kayden Tanner
LBLuke D. Bass
Luke D. Bass
CKChris Kawcak
Chris Kawcak
LSLauren V Schnabel
Lauren V Schnabel
KHK. L. Hallowell
K. L. Hallowell
LPLynn M. Pezzanite
Lynn M. Pezzanite
Summary: Intra‐articular (IA) corticosteroid administration in equine athletes has gained increased attention recently, particularly in racing. Despite widespread corticosteroid use in equine practice for decades, there are still a lack of equine‐specific studies to address key questions related to their use. Extrapolation of best practices from human literature supports that while IA corticosteroids elicit transient symptom‐modification of osteoarthritis (OA), they can have deleterious effects on articular cartilage depending on drug selection, dose and time‐ indicating the lowest efficacious dose should be used to achieve clinical benefit. While there are limited data supporting current clinical protocols related to dose or injection frequency diminishing returns have been noted with multiple‐injection protocols. Recent studies have led to heightened awareness of equine endocrinopathies and the sensitivity of equine patients with those disorders to the effects of steroids, putting them at increased risk for complications such as laminitis and secondary infection. These findings prompt reconsideration of long‐term or high‐dose corticosteroid administration, particularly given the evolution of alternative IA orthobiologic and immunomodulatory therapies for OA, which require further investigation and comparison for relative modification of clinical signs and disease progression. As much of the referenced literature does not permit direct comparisons across studies, further research is needed to compare corticosteroids at equivalent body doses and dosing intervals in horses with and without endocrinopathies. Without such studies, definitive evidence linking IA corticosteroid use to laminitis risk, subchondral bone injury or catastrophic injury is lacking at this time. This narrative review seeks to summarise the current literature available as well as gaps in knowledge on equine IA corticosteroid use for the practising clinician.

21 May 2026 in Animals
Verified
Journal Article
Open access
PDF file
KTKayden Tanner
Kayden Tanner
MMMarshall Mays
Marshall Mays
TNThu Annelise Nguyen
Thu Annelise Nguyen
TLTomas Lugo
Tomas Lugo
Multisystemic eosinophilic epitheliotropic disease (MEED) is a rare and severe equine disorder characterized by chronic eosinophilic inflammation, epithelial disruption, and multi-organ involvement, with an undefined genetic basis. We performed the high-depth (~40×) whole-genome sequencing of an affected horse and compared it to 40 control genomes. Over 6.3 million variants were identified, with moderate- and high-impact variants enriched in low-frequency categories, including rare and private variants absent from the controls. The affected horse was dominated by missense mutations, with relatively few high-impact variants, consistent with the distributed protein-altering effects rather than a single highly penetrant mutation. Gene prioritization and pathway analyses highlighted the disruption of cytoskeletal organization, microtubule dynamics, epithelial integrity, and immune regulation. The network analysis further revealed the interconnected structural and inflammatory pathways, suggesting a link between an impaired epithelial barrier function and immune homeostasis. Together, these findings provide the first population genomic insight into MEED and support a model in which cumulative mutations contribute to the epithelial instability and persistent inflammation characteristic of the disease.